These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 20210682

  • 1. Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid.
    Schima SM, Maciejewski SR, Hilleman DE, Williams MA, Mohiuddin SM.
    Expert Opin Pharmacother; 2010 Apr; 11(5):731-8. PubMed ID: 20210682
    [Abstract] [Full Text] [Related]

  • 2. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S.
    Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M, LCP-AtorFen Investigators.
    Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
    [Abstract] [Full Text] [Related]

  • 4. Fenofibric acid: in combination therapy in the treatment of mixed dyslipidemia.
    Yang LP, Keating GM.
    Am J Cardiovasc Drugs; 2009 Dec; 9(6):401-9. PubMed ID: 19929038
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin.
    Yiu KH, Cheung BM, Tse HF.
    Expert Opin Investig Drugs; 2010 Mar; 19(3):437-49. PubMed ID: 20141348
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.
    Goldberg AC, Bittner V, Pepine CJ, Kelly MT, Thakker K, Setze CM, Lele A, Sleep DJ.
    Am J Cardiol; 2011 Mar 15; 107(6):898-905. PubMed ID: 21247520
    [Abstract] [Full Text] [Related]

  • 8. [Lipid-lowering cardiovascular prevention in type 2-diabetes. Statins are effective according to the FIELD study].
    Båvenholm P, Attvall S, Nilsson PM.
    Lakartidningen; 2011 Mar 15; 103(35):2462-6. PubMed ID: 17002161
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study.
    Mohiuddin SM, Pepine CJ, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC.
    Am Heart J; 2009 Jan 15; 157(1):195-203. PubMed ID: 19081418
    [Abstract] [Full Text] [Related]

  • 10. Management of dyslipidemia in diabetes.
    Solano MP, Goldberg RB.
    Cardiol Rev; 2006 Jan 15; 14(3):125-35. PubMed ID: 16628021
    [Abstract] [Full Text] [Related]

  • 11. Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease.
    Olsson AG.
    Expert Opin Pharmacother; 2010 Jul 15; 11(10):1715-26. PubMed ID: 20518616
    [Abstract] [Full Text] [Related]

  • 12. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.
    Jones PH.
    Am J Cardiol; 2007 Feb 19; 99(4A):133B-140B. PubMed ID: 17307065
    [Abstract] [Full Text] [Related]

  • 13. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
    Cardenas GA, Lavie CJ, Cardenas V, Milani RV, McCullough PA.
    Rev Cardiovasc Med; 2008 Feb 19; 9(4):239-58. PubMed ID: 19122582
    [Abstract] [Full Text] [Related]

  • 14. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E, Laforest L, Burke T, Phatak H, Souchet T.
    Clin Ther; 2007 Aug 19; 29(8):1671-81. PubMed ID: 17919548
    [Abstract] [Full Text] [Related]

  • 15. Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol.
    Gotto AM, Farmer JA.
    Nat Clin Pract Cardiovasc Med; 2006 Dec 19; 3(12):664-72. PubMed ID: 17122799
    [Abstract] [Full Text] [Related]

  • 16. The treatment of dyslipidemia--what's left in the pipeline?
    Rau O, Zettl H, Popescu L, Steinhilber D, Schubert-Zsilavecz M.
    ChemMedChem; 2008 Feb 19; 3(2):206-21. PubMed ID: 17963209
    [Abstract] [Full Text] [Related]

  • 17. A triumvirate of targets in the prevention and treatment paradigm for cardiovascular disease.
    Packard C.
    Atheroscler Suppl; 2006 Apr 19; 7(1):21-9. PubMed ID: 16504600
    [Abstract] [Full Text] [Related]

  • 18. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.
    Robinson JG.
    Am J Cardiol; 2008 Apr 01; 101(7):1009-15. PubMed ID: 18359323
    [Abstract] [Full Text] [Related]

  • 19. Statins and LDL-cholesterol lowering: an overview.
    Stroes E.
    Curr Med Res Opin; 2005 Apr 01; 21 Suppl 6():S9-16. PubMed ID: 16138936
    [Abstract] [Full Text] [Related]

  • 20. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
    Meas T, Laloi-Michelin M, Virally M, Peynet J, Giraudeaux V, Kévorkian JP, Guillausseau PJ.
    Eur J Intern Med; 2009 Mar 01; 20(2):197-200. PubMed ID: 19327612
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.